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How to match the optimal currently available inhaler device to
an individual child with asthma or recurrent wheeze
Wim M van Aalderen1, Luis Garcia-Marcos2, Monika Gappa3, Warren Lenney4, Søren Pedersen5, Richard Dekhuijzen6 and David Price7
Inhaled medications are the cornerstone of treatment in early childhood wheezing and paediatric asthma. A match between
patient and device and a correct inhalation technique are crucial for good asthma control. The aim of this paper is to propose an
inhaler strategy that will facilitate an inhaler choice most likely to beneﬁt different groups of children. The main focus will be on
pressurised metered dose inhalers and dry powder inhalers. In this paper we will discuss (1) practical difﬁculties with the devices
and with inhaled therapy and (2) the optimal location for deposition of medicines in the lungs, and (3) we will propose a practical
and easy way to make the best match between the inhaler device and the individual patient. We hope that this paper will
contribute to an increased likelihood of treatment success and improved adherence to therapy.
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INTRODUCTION
Inhaled medications are the cornerstone of treatment in early-
childhood wheezing and paediatric asthma. They should be
targeted to areas in the lungs where they will be most effective.
Treating paediatric asthma (children aged 5 years or older) with
inhaled corticosteroids (ICSs) and bronchodilators has resulted in
improvements in asthma control.1 In early-childhood wheezing
(0–4 years), treatment outcomes are less positive probably
because of diverse clinical phenotypes. In this young age it is
difﬁcult to achieve and maintain an optimal inhalation
technique.2,3
The most important advantage of inhaled delivery of medicines
is that they are delivered directly into the airways and lungs,
resulting in higher local concentrations, lower systemic exposure
and fewer systemic side effects compared with the oral or
intravenous route. However, inhalation of medicines can be
complicated and difﬁcult for some children. Drug deposition in
the lungs depends on the type of inhaler device, the character-
istics of the inhaled medicine, and on patient-related
characteristics.4
There are many reports of treatment failure due to poor
inhalation technique.5 The number of inhalation devices is
immense. Physicians and pharmacists who prescribe and supply
them may lack knowledge on the best choice of device for each
individual or may be unaware of the speciﬁc inhalation technique
that best matches the patient’s needs.
Several studies have demonstrated that large numbers of
patients do not use their inhalers correctly, thereby gaining little
or no therapeutic beneﬁt from the prescribed treatment.6–8
Focussing on which inhalers are the easiest to use correctly by
children of varying ages is at least as important as the in vitro
output characteristics of any inhaler. Because of patient hetero-
geneity, no single inhaler will satisfy the needs of all. This
is particularly true in children where different age groups
possess different psychomotor skills. Cost is another important
consideration, but will vary from country to country and is beyond
the scope of this review.
The aim of this paper is to propose an inhaler strategy that will
facilitate an inhaler choice most likely to beneﬁt different groups
of children. The main focus will be on pressurised metered-dose
inhalers (pMDIs) and dry powder inhalers (DPIs), highlighting
practical difﬁculties with the devices and with inhaled therapy. In
addition, we will discuss the optimal location for depositing the
medicines in the lungs. Finally, we will propose a practical and
easy way to make the best match between the inhaler device and
the individual patient. The hope is that this will improve
consistency of inhaler prescribing in primary and secondary care,
in children with early-childhood wheeze and asthma (Box 1).
DIFFICULTIES WITH INHALED THERAPY
A device that is easy to use and also allows optimal lung
deposition seems crucial for disease control. This is particularly
important for ICSs and short-acting β2-agonists.
The optimal inhalation technique differs between devices. Many
children experience problems using their inhaler correctly,
resulting in poor asthma control.5 Meta-analyses (including studies
in children from 7 months and older) indicate that if the correct
inhaler technique is taught, different devices produce similar
clinical outcomes.9,10 However, patients and parents were well
trained in device usage and some were excluded if they were
unable to inhale correctly.
Poor inhaler technique was found in 70% of 3,955 asthma
patients who used a pMDI and was associated with decreased
asthma stability.6 Other studies have reported poor inhaler
technique in 32–96% of patients.7,11 Inhalation technique often
remains poor after several teaching sessions.10 Comprehensive
training and repeated checks are needed to ensure a reliable
inhalation technique.12 Many physicians have poor knowledge
and training in the correct use of inhaler devices,13 resulting in
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inconsistency in the choice of inhaler device and lack of
explanation and training.
Education and perception
Before starting inhaled therapy, an explanation about the aims of
treatment must be given. The key question to ask when regular,
preventative therapy fails is whether the child is actually taking
the medication. Parents are naturally concerned about the
possible side effects of ICSs, such as growth retardation and
dependence on medicines.14,15 A recent long-term follow-up
study in children with asthma who were treated for at least 4 years
with budesonide (BUD) or nedocromil indicated that children who
used ICSs were 1 cm shorter with respect to their ﬁnal height
compared with the group that used nedocromil (a non-steroid
anti-asthma drug).16 Possible barriers need discussion; a dialogue
between careprovider and family should result in a shared
perception about the disease and its treatment goals leading to
a good starting point for eventual successful management and
control.17–19
Requirements for inhalation
The requirements for inhalation are different for very young
children. The deposition in the lower airways during crying is
markedly reduced.20,21 The facemask seal is critical for efﬁcient
aerosol delivery to infants and young children.22,23 There are also
differences in anatomy and physiology of the upper airways: the
pharynx and supraglottic area are less rigid; the epiglottis is
narrow and ﬂoppy and closer to the palate; and the larynx is
higher and close to the base of the tongue.3 Delivery through the
nose has been shown to be less effective than through the mouth,
probably because of higher resistance, the high ﬂow rate and
increased turbulence in the nostrils and the nasopharynx.24,25
High inspiratory ﬂows cause impaction of drug particles in the
upper airways, especially the larger particles (3–5 μg).26 Smaller
particles, inhaled with lower inspiratory ﬂows, have a greater
chance to bypass the upper airways and deposit in the lower
airways. Young children are not able to hold their breath and are
more likely to exhale much of their medication. Amirav et al.
reviewed the differences in lung deposition of aerosol therapeu-
tics with large and small particles and concluded that small-
particle aerosols provide better deposition than larger ones in
young children.3
Children 7 years and older usually have a sufﬁcient inspiratory
ﬂow rate to inhale through all of the different types of inhalers,
such as pMDI–spacer combinations, breath-actuated inhalers (BAI)
and DPIs.
Current prescribing shows a range of devices being used, some
of which may have advantages in certain patients over a pMDI
plus spacer, and we have therefore set out to explain when they
can and cannot be used.
PRACTICAL DIFFICULTIES IN THE USE OF INHALERS
Pressurised metered-dose inhalers
These are widely used in the treatment of childhood asthma and
in young children with recurrent wheezing. An aerosol dose is
generated by the patient pressing down the canister into the
actuator seating. Canisters of suspension aerosols should be
shaken. A good press and breathe (hand–breath) coordination is
needed to inhale the medication into the peripheral airways. With
the introduction of HydroFluoroAlkane propellants, some aerosols
kept their initial characteristics (large particle size, high velocity),
such as ﬂuticasone propionate (FP) and beclomethasone dipro-
pionate (BDP; Clenil, GlaxoSmithKline, London, UK), but some
aerosols have changed characteristics; for example, extra-ﬁne
HydroFluoroAlkane BDP (Qvar, Teva Pharmaceuticals, Tel Aviv,
Israel) changed to a smaller median mass aerodynamic diameter
(‘median particle size’; 1.1 μm).
The use of a pMDI looks simple: ‘press and breathe’. However, it
is complex because it requires hand–breath coordination and the
need to breath-hold afterwards. Poor hand–breath coordination
results in reduced lung deposition.26 Almost all children and adults
with asthma have problems in coordinating the pMDI actuation
together with their inhalation of the released aerosol.27–29 One way
to solve this poor coordination is the use of a valved holding
chamber or spacer.30 Another possibility in children 7 years or older
and in adults is a breath-actuated device.31
Breath-holding after inhalation is essential for an optimal
deposition of the inhaled medication in the smaller airways.32
A breath-hold pause of 5 s is suggested in children up to 10 years
of age. This recommendation is based on a study in trained
5–17-year-old children who inhaled extra-ﬁne HydroFluoroAlkane
BDP via an AeroChamber-Plus (Trudell, London, ON, Canada) with
a mouth piece.30 Lung (ﬁlter) deposition was highest in the group
that breath-held (56.6% in 5–7-year-olds, 56.6% in 8–10-year-olds,
and 58.4% in 11–17-year-olds) compared with the group that took
ﬁve tidal breaths (35.4% in 5–7-year-olds, 47.5% in 8–10-year-olds
and 54.9% in 11–17-year-olds).
pMDI–spacer combination
pMDI–spacer combinations can be used by almost everyone. They
overcome hand–breath coordination difﬁculties and decrease oro-
pharyngeal deposition, thereby increasing deposition into the
lower airways. Because the larger aerosol particles deposit in the
spacer, local unwanted side effects in the mouth and throat, such
as thrush and hoarseness, are much reduced.
The volume of the spacer is important, especially for young
children with low tidal volumes. Higher aerosol concentration in
the smaller volume chambers increases drug delivery to where
it is needed.33 Multiple breaths may also increase drug
delivery into the airways. Schultz et al.34 recorded the breathing
patterns in 2–7-year-old children inhaling placebo using four
different spacers. Two tidal breaths were adequate to inhale
the aerosol using small-volume spacers (Aerochamber Plus,
Funhaler, ITL design & Manufacturing, Eveleigh NSW, Australia)
and three tidal breaths were adequate using the larger spacer
(Volumatic, GlaxoSmithKline).
Other factors also inﬂuence the variation in the delivered dose.
The electrostatic charge in a spacer reduces delivery into the lung.
In a randomised crossover study Janssens et al.35 investigated
children with stable asthma aged 1–4 years and 5–8 years. They
assessed the dose variability delivered to the mouth through a
metal Nebuchamber (AstraZeneca, Luton, UK) (no electric charge)
Box 1 Manuscript selection
This review contains many different subjects that are often
substantiated by limited evidence in the literature, such as
device characteristics, optimal inhalation technique for a speciﬁc
device, age speciﬁcity of devices and so on. Many devices lack
documentation of their characteristics. Other factors that may
inﬂuence an optimal outcome of inhaled therapy are the limited
knowledge of physicians about the different devices and
adherence to treatment. For this reason no systematic review
was performed.
We aimed to write a practical guide for optimal inhalation for
the individual child. Advice is based on the scientiﬁc and clinical
experience of the authors, including a review of relevant
references from the recent European Respiratory Society task
force on inhalation devices.4
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and through two plastic spacers: the Babyhaler (Glaxo Wellcome,
Greenford, UK) in 1–4-year-olds and the Volumatic in 5–8-year-
olds. They found substantial within-subject dose variability in
aerosol delivery. The variability was lower for the metal spacer
(currently rarely used) than for the plastic spacer in the 5–8-year
age group. The dose delivered to the mouth through the metal
spacer was twice that delivered through the plastic spacers.
The dose delivered through a spacer also varies with a child’s
age and with the child’s breathing pattern. Lung deposition was
determined in two groups of asthmatic children. All inhaled ﬁve
puffs of radio-labelled salbutamol pMDI through a plastic spacer:
the younger group (up to 48 months) used a Babyhaler with a
facemask and the older group (⩾48 months) used a Volumatic.
The younger children used ﬁve tidal breaths between actuations.
The older children inhaled with ﬁve tidal breaths or one single
slow breath with maximal inhalation and held their breath for 10 s.
Lung deposition varied from 16.4% in the younger children to 28.2
or 41.8% in the older group inhaling with different breathing
patterns.36 Table 1 shows the wide differences in lung deposition
in children inhaling with a pMDI and spacer combination and with
different breathing patterns.
The practical conclusion that can be drawn from these data is
that young children up to 7 years most beneﬁt from inhalation
with small-volume spacers.33,37 Most children aged 4 years or
older (and sometimes even younger) can use a spacer with a
mouthpiece, and the younger children should use a spacer with a
mask. Children aged 4 years or older are able to hold their breath
for 5–7 s, which improves the lung deposition of the drug.
Breath-actuated inhalers
Breath-actuated metered dose inhalers may overcome hand–
breath coordination problems. They release a dose of aerosol
triggered by a relatively low inspiratory ﬂow rate (Autohaler 30 l/
min (3M, St Paul, MN, USA), Easibreath (PA, London, UK) or
Redihaler 20 l/min (Teva Pharmaceuticals, Waterford, Ireland)).
They contain extra-ﬁne HydroFluoroAlkane BDP or salbutamol.
Because of the short and limited inspiratory ﬂow of young
children they are advised to be used in children aged 7 years or
older. A deposition study in children aged 5–14 years showed an
age-dependent lung deposition from 36.9% up to 54.1% in the
older children.38,39
Dry powder inhalers
DPIs, such as the Turbuhaler (Astra Zeneca, Lund, Sweden) and the
Diskus (GlaxoSmithKline), require a rapid and forceful inhalation.
Medication is delivered to the lungs after a deep inhalation
through the DPI. Most DPIs contain micronised drug blended with
larger lactose particles. These particles are too large to be inhaled,
and hence release of the drug particles from carrier particles is
needed. The energy for dispersion is derived from the inhaled
airstream. The more forceful the inspiratory ﬂow through the DPI,
the higher the fraction of released drug particles, the higher the
total lung dose and the greater the ﬁne particle fraction.40 The
advantage of DPIs in children with sufﬁcient inspiratory ﬂow is that
they overcome hand–breath coordination problems. Disadvan-
tages are that the delivered dose is inspiratory ﬂow and
acceleration dependent. Another disadvantage in younger children
(e.g., 4–6 years old) is that inhalation may be effective when the
child is well but may be insufﬁcient during a period of wheezing.41
The variability of the delivered dose from DPIs is greater than
that from pMDIs.40 The median mass aerodynamic diameter of the
Turbuhaler with a low ﬂow (30 l/min) was 6.23 μm, whereas it
decreased to ~ 2.28 μm with an inspiratory ﬂow of 60 l/min.40
When the Diskus and Turbuhaler were compared for the delivery
of FP and BUD, the results showed that the Diskus delivered 87–
93% of the label claim, whereas the Turbuhaler delivered 40–
58%.42 Increasing the inspiratory ﬂow through the Turbuhaler
from 30 l/min to 60 l/min and to 90 l/min resulted in an increase in
BUD delivery from 37.5 to 64.4 to 107.4% of the label claim dose,
and the ﬁne particle mass more than doubled.41 In the only in vivo
study, Agertoft and Pedersen compared the lung deposition of
BUD inhaled from the Turbuhaler and that of FP inhaled from
Table 1. Mean lung deposition in children with a pMDI spacer combination
Author/Journal Age Device Breathing pattern Drug Mean lung deposition
Agertoft and Pedersen37
Arch Dis Child, 1994
10–25mo Nebuhaler (750ml)
Aerochamber
Babyspacer
30 s tidal breathing
30 s tidal breathing
30 s tidal breathing
Budesonide 26.7% (17–44)
19.7% (9–33)
27.7% (19–38)
Tal et al.55
J Pediatrics, 1996
0.25–5 y pMDI -Aerochamber 30 s tidal breathing Salbutamol 1.97% (1.4)
Wildhaber et al.56
J Pediatrics, 1999
2–4 y
5–9 y
pMDI- Aerochamber 5 Tidal breaths
in the 5–9-y group
Salbutamol 5.4% (2.1)
9.6% (3.9)
Wildhaber et al.36
J Pediatrics, 2000
o48mo
⩾ 48mo
Babyhaler
Volumatic
Volumatic
Tidal breathing
Tidal breathing
Single breath
Sabutamol 16.4% (5.5)
28.2% (6.7)
41.8% (3.8)
Roller et al.30
Eur Respir J, 2007
5–7 y
8–10 y
11–7 y
5–7 y
8–10 y
11–7 y
Aerochamber
Aerochamber
Tidal breathing
Breath-hold
Extra-ﬁne HFA beclomethasone
Extra-ﬁne HFA beclomethasone
35.4% (8.3)
47.5% (13.0)
54.9% (11.2)
58.1% (6.6)
56.6% (5.2)
58.4% (9.2)
Schulz et al.34
Pediatrics, 2010
2–7 y Aerochamber plus 2 Tidal breaths
9 Tidal breaths
Funhaler
2 Tidal breaths
9 Tidal breaths
Volumatic
2 Tidal breaths
9 Tidal breaths
Salbutamol 40% (95% CI: 34–46%)
41% (95% CI: 36–47%)
39% (95% CI: 34–43%)
38% (95% CI: 35–42%)
37% (95% CI: 33–41%)
43% (95% CI: 40–46%)
Mean lung deposition (Agertoft), expressed as a percentage of the metered dose± range, or (Schulz) as 95% conﬁdence interval (CI), or (Tal, Wildhaber, Roller)
expressed as s.d.
Abbreviations: HFA, hydroﬂuoroalkane-134a; pMDI, pressurised metered-dose inhaler.
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Diskus.43 The mean lung deposition in children aged 8–14 years
after Turbuhaler and Diskus inhalation was 30.8 and 8%,
respectively, when inhalation of BUD and FP took place on
separate days and 29.5 and 7.6%, respectively, when inhaled on
the same day. These in vivo data indicate a fourfold higher
deposition from Turbuhaler than from Diskus.43 In another study
in which the breathing pattern of 4–8-year-old children was
simulated,44 the total emitted dose of FP Diskus was compared
with that of BUD Turbuhaler. An overall 87–89% of the label claim
was emitted from the Diskus compared with 56–62% from the
Turbuhaler. However, the ﬁne particle fraction was slightly lower
from the Discus compared with the Turbuhaler (15–18% vs. 21–
23%). For both devices, there was an inverse relationship between
inspiratory ﬂow rate and particle size
The Novolizer (Sofotec GmbH & Co. KG, Frankfurt, Germany) is a
more recently developed breath-activated multidose reﬁllable DPI
with dose counter. It has the advantage of a feedback mechanism
that guides the patient through the correct inhalation
manoeuvre.45 A study in 4–11-year-old children showed that they
were capable of generating twice the minimal PIF (35–50 l/min) to
overcome the trigger threshold of the Novolizer.46 The novolizer
may contain BUD, salbutamol or formoterol. The particle size
dependency of the ﬂow rate is less apparent in the Novolizer as in
other DPIs.45
However, clinical head-to-head studies in different age groups
should be performed to investigate whether these differences
have any clinical relevance.
Table 2 shows an age indication of the different types of
inhalers.
WHERE SHOULD INHALED CORTICOSTEROIDS AND
β2-AGONISTS BE DELIVERED?
The most important inhaled medicines for the treatment
of asthma and early-childhood wheezing are β2-adrenergic
bronchodilators and ICSs. The inﬂammatory process involves the
entire airway and, as corticosteroid receptor density increases in
the peripheral airways,47 ICS delivery to small airways is important.
As β2 receptors are found equally in the large and smaller airways,
targeting wide areas of the airways may be important for
bronchodilators as well.48,49
Small-particle ICSs, such as ultra-ﬁne HydroFluoroAlkane BDP
aerosol and ciclesonide, may offer a potential beneﬁt in young
children with smaller airways.50 These characteristics may be
particularly relevant in young children in whom more airways are
classiﬁed as small (o2mm in diameter) and whose airway
resistance is high.51
Recommended doses according to the GINA guidelines are
shown in Table 3.
MAKING THE OPTIMAL MATCH BETWEEN INHALATION DEVICE
AND THE INDIVIDUAL PATIENT
Before prescribing an inhaler device the following questions may
be helpful to choose the correct device for the individual patient.
Table 2. Age indication of the different types of inhalers
0–3 y 4–6 y 7 y and older
pMDI + Spacer (small) with mask
10 times tidal breathing
+ Spacer (small) with mouth piece
2 deep breaths
5–7 s breath-holding
+ Spacer with mouth piece
1 deep breath
7 s breath-holding
DPI − − Quick and forcefully deep inhalation
5–7 s breath-holding
BAI − − Normal deep inhalation
5–7 s breath-holding
Abbreviations: BAI, breath-actuated inhaler; DPI, dry powder inhaler; pMDI, pressurised metered-dose inhaler.
Table 3. Dose indication of different inhaled corticosteroids
Equipotent doses of ICS for adults and children older than 5 years Low daily doses of ICS in children⩽ 5 years
Drug Low dose
(μg)
Medium daily
dose (μg)
High daily
dose (μg)
Products available
in different countries
Drug Low daily dose (μg)
Beclomethasone
dipropionate—CFC
200–500 4500–1,000 41,000–2,000 Beclomethasone
Clenil
Becotide
Beclomethasone
dipropionate
100
Extra-ﬁne Beclomethasone
dipropionate—HFA
100–250 4250–500 4500–1,000 Qvar
Aerobec
Budesonide MDI+spacer
Budesonide nebulised
200
500
Budesonidea 200–400 4400–800 4800–1,600 Budesonide
Pulmicort
Ciclesonidea Not studied in
this age group
Ciclesonidea 80–160 4160–320 4320–1,280 Alvesco Fluticasone propionate 100
Flunisolide 500–1,000 41,000–2,000 42,000 Aerobid Mometasone furoate Not studied in
this age group
Fluticasone propionate 100–250 4250–500 4500–1,000 Fluticasone
Flixotide
Triamcinolone acetonide Not studied in
this age group
Mometasone furoatea 200 4400 4800 Asmanex
Triamcinolone acetonide 400–1,000 41,000–2,000 42,000 Triamcinolone
Comparisons based on efﬁcacy data. Doses according to GINA guidelines.1
Abbreviation: ICS, inhaled corticosteroid.
aApproved for once daily dosing in mild patients.
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Who?
What is the age of the child? Can he/she consciously inhale?
Young infants and disabled children are not aware how to inhale.
Young children have a low inspiratory ﬂow and are not able to
hold their breath.
Where?
In children with asthma and in those with early wheezing the
small airways should be targeted. Small-particle ICSs may have an
advantage because of higher deposition in the small airways.3 The
clinical relevance in children for small-particle drugs is weak and
mainly based on the ﬁndings from a double-blind randomised
controlled trial and from one real-life study. In a double-blind
randomised controlled dose reduction study in school-aged
children, extra-ﬁne HydroFluoroAlkane BDP pMDI plus spacer
proved to be equally effective compared with FP pMDI plus
spacer.52 However, in a real-life comparative effectiveness study,
increasing the extra-ﬁne HydroFluoroAlkane BPP dose appeared
to provide improved outcomes (signiﬁcantly better asthma control
and signiﬁcantly fewer exacerbations) compared with stepping
up ICS as FP or adding a separate long-acting beta-agonist
(signiﬁcantly better asthma control); similar outcomes were seen
when compared with a ﬁxed-dose combination of ICS/long-acting
β2-agonist.
53
How?
Age can act as a relative proxy for insufﬁcient inspiratory ﬂow.
Under 7 years of age there is insufﬁcient inspiratory ﬂow to inhale
a DPI or a BAI; it is also not possible to teach these young children
to hold their breath.54 The only options here are a pMDI–spacer
combination, with tidal breathing (5–10 times) after actuation.
Medicines delivered through nebulisers should not be used as
ﬁrst-line prescriptions in primary care because higher dosages are
licensed with a greater possibility of adverse effects and expense.
Especially short-acting β2-agonists in very young children should
be nebulised with oxygen rather than air as the ﬂow gas because
of the danger of arterial oxygen desaturation.
A DPI or a BAI can be used from 7 years of age. The problem
with a breath-actuated device in children from 4 to 6 years of age
is that their inspiration time is too short to complete an effective
inhalation.
For children aged 3 years or lower, a pMDI–spacer combination
with a face mask can be used. In children aged 4 years or older, a
pMDI–spacer combination with a mouth piece is preferred. Above
6 years of age many different inhalers may be effective.
The optimal choice for an inhaler device can be summarised in
the following two questions and in the use of one algorithm
(Figure 1) to make the correct choice for the individual patient.
1. Is the patient conscious of his/her inhaling?
Young children (6 years or younger) or children who are
mentally not able to follow instructions about a correct
inhalation technique should use a pMDI plus spacer and not
a pMDI without a spacer, DPI or breath-actuated aerosol.
2. Is his/her inspiratory ﬂow sufﬁcient?
Young children with an insufﬁcient inspiratory ﬂow (6 years or
younger) or children with insufﬁcient muscular power to inhale
forcefully should not use DPIs or breath-actuated aerosols.
CONCLUSION
A wrong inhaler technique or inhaler device is one of the most
prevalent causes of poor asthma control. An optimal choice for the
individual patient, device training and repeated checks of patients'
device use and technique are essential for good asthma control.
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